selective betablocking agents have adverse effects on

glucose metabolism, prolong hypoglycaemia or mask

hypoglycaemic symptoms. In diabetic nephropathy

betablockers are as nephroprotective as ACEI. Given

the proven primary and secondary cardioprotective

effect in antihypertensive treatment and after myocardial

infarction, there is no evidence-based reason

to withhold these agents from diabetic patients.